ArticleDrug design, development and therapy2026
Efficacy and Safety of Ranibizumab Combined with Dexamethasone Intravitreal Implant Sequential Therapy for Macular Edema Secondary to Non-Ischemic Retinal Vein Occlusion.
Article in Drug design, development and therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: To evaluate the efficacy, safety, and treatment burden of intravitreal ranibizumab (RBZ) combined with a dexamethasone (DEX) intravitreal implant compared to ranibizumab monotherapy for macular edema (ME) secondary to non-ischemic retinal vein occlusion (RVO). Methods: This retrospective controlled study included 138 patients (139 eyes) with treatment-naïve non-ischemic RVO-ME (including both branch and central retinal vein occlusions) diagnosed at Sanmenxia Eye Hospital between 2020 and 2024. Eyes were categorized into two groups: the monotherapy group (RBZ, n=68), receiving standard "3+PRN" ranibizumab; and the combination group (RBZ+DEX, n=71), receiving sequential therapy comprising an initial ranibizumab injection followed by a DEX implant (Ozurdex) within 2-4 weeks, with subsequent PRN retreatment. Primary outcomes included mean change in best-corrected visual acuity (BCVA) and central macular thickness (CMT), as well as the proportion of eyes achieving clinically significant visual gain (>0.3 logMAR) and anatomical resolution (CMT <300 μm). Secondary outcomes quantified treatment burden (injection frequency) and safety profiles. To address potential confounding variables between the two RVO subtypes, all outcomes were further evaluated through a stratified subgroup analysis. Results: From month 3 to month 9, the RBZ+DEX group showed significantly greater mean BCVA improvement than the RBZ group ( Conclusion: Sequential therapy with ranibizumab and dexamethasone implant offers superior clinical efficacy over ranibizumab monotherapy for RVO-ME. This regimen leverages a synergistic mechanism to provide better mid- to long-term visual gains, faster anatomical restoration, and a reduced treatment burden. The safety profile remains favorable with manageable risks.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.